PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

UCLA researchers develop risk calculator to predict survival in heart failure patients

2014-01-22
(Press-News.org) Contact information: Rachel Champeau
rchampeau@mednet.ucla.edu
310-794-2270
University of California - Los Angeles Health Sciences
UCLA researchers develop risk calculator to predict survival in heart failure patients A UCLA team has developed an easy-to-use "risk calculator" that helps predict heart failure patients' chances of survival for up to five years and assists doctors in determining whether more or less aggressive treatment is appropriate.

Given that heart failure impacts more than 5 million Americans and numerous variables affect patient outcomes, this type of risk-assessment tool can be very helpful to physicians and patients in assessing prognosis over time and guiding medical decision-making, the researchers say.

Their new risk model is featured in the January edition of the journal Circulation: Heart Failure.

Since heart failure manifests differently in men and women, the team initially sought to create a sex-specific risk model for greater accuracy, an approach that hadn't been taken before. But they discovered that separate risk models for men and women weren't necessary.

"We were extremely surprised that the same exact top predictors of risk were identical in both men and women," said senior author Dr. Tamara Horwich, an assistant professor of medicine in the cardiology division at the David Geffen School of Medicine at UCLA. "We ultimately only needed to create one unified heart failure risk model for both sexes."

Heart failure occurs when the heart can no longer pump enough blood to the body's other organs. Often, patients with heart failure have reduced left-ventricle ejection fraction, which indicates a lowered volume of blood being pumped out of this heart chamber with each beat of the heart.

In developing the risk calculator, the UCLA team used data from 2,255 heart failure patients, including 1,569 men and 686 women, who were referred to the Ahmanson–UCLA Cardiomyopathy Center between 2000 and 2011. They collected 39 patient variables, including information like age, weight, medications, lab work and the results of diagnostic tests such as echocardiography — the use of ultrasound to investigate the action of the heart.

The team assessed each variable in terms of predicting the following serious risks: mortality, the need for an urgent transplant, and the need for a mechanical pump known as a ventricular assist device. Using a complex statistical analysis, they determined that four of the 39 factors were predictive of these serious risks in both men and women and could predict survival over a five-year period.

The four variables included:

B-type natriuretic peptide level
This peptide (BNP) is a substance secreted from the ventricles, or lower chambers of the heart, in response to changes in pressure. The level of BNP in the blood increases when heart failure symptoms worsen and decreases when the condition is more stable.

Peak oxygen consumption
Peak oxygen consumption (PkVO2), the maximum rate of oxygen used during exercise, is tested when a patient is on a treadmill or bike. Levels of oxygen get lower as heart failure worsens.

New York Heart Association classification
This classification places a patient in one of four categories depending on how limited they are during physical activity. The limitations are related to breathing, shortness of breath and angina chest pain.

Heart failure medications
Patients may be taking a common heart failure medication — an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB).

Although women had many characteristics that differed from men — for instance, younger age at heart failure diagnosis, with higher ejection fraction — and had less coronary artery disease, these four key variables still proved the best in assessing risk in both sexes.

To develop the risk model, the researchers used data from patients referred to UCLA from 2000 to 2007. They then tested and validated its use with information on patients seen from 2008 to 2011.

"The model was just as effective in predicting risk in early as well as later years, when newer heart-failure treatments had emerged," said first author Jennifer Chyu, a UCLA student researcher at the time of the study who is now at the University of Washington.

According to Horwich, the risk calculator can currently be used via an Excel spreadsheet. The team also is actively working on developing a phone app of the calculator that will be even simpler; a doctor could simply enter in the four facts about a patient and the model would instantly calculate the annual survival risk up to five years.

"Physicians can begin to use the new UCLA tool right away for their advanced heart failure patients, to calculate survival risk," said study author Dr. Gregg C. Fonarow, UCLA's Eliot Corday Professor of Cardiovascular Medicine and Science and director of the Ahmanson–UCLA Cardiomyopathy Center.

For example, Fonarow said, patients at very high risk based on the calculator might consider very aggressive therapies such as a heart transplant or the surgical implantation of a heart assist device. Patients at lower risk may be able to avoid excess treatment.

The new UCLA risk calculator also performed better when tested against several other risk-prediction models, including the Seattle Heart Failure Model and the Heart Failure Survival Score.

The next step, according to Horwich, is testing the accuracy and utility of the UCLA model in a larger sample of patients.

INFORMATION:

The study was funded by the Iris Cantor–UCLA Women's Health Center and the Ahmanson Foundation.

Chi Hong Tseng of the department of medicine at the David Geffen School of Medicine at UCLA also contributed to the study.

For more news, visit the UCLA Newsroom and follow us on Twitter.

END



ELSE PRESS RELEASES FROM THIS DATE:

New CU-Boulder study shows differences in mammal responses to climate change

2014-01-22
New CU-Boulder study shows differences in mammal responses to climate change Shrews 27 times less likely to respond to climate change than moose If you were a shrew snuffling around a North American forest, you would be 27 times ...

Modest familial risks for multiple sclerosis

2014-01-22
Modest familial risks for multiple sclerosis Even though multiple sclerosis is largely caused by genetic factors, the risk of patients' relatives developing the disease is lower than previously assumed. This is the conclusion of a new population registry-based study, ...

Bright star reveals new exoplanet

2014-01-22
Bright star reveals new exoplanet By studying the star around which the planet revolves, they found that the star's rotation appears to be well-aligned with the planetary movement. The object can be well-studied because the star is relatively bright, it can ...

Drug alternatives to antibiotics may not be perfect, study shows

2014-01-22
Drug alternatives to antibiotics may not be perfect, study shows New types of drug intended for use in place of antibiotics have been given a cautious welcome by scientists. Researchers have been probing the long-term effectiveness of drugs currently ...

From a carpet of nanorods to a thin film solar cell absorber within a few seconds

2014-01-22
From a carpet of nanorods to a thin film solar cell absorber within a few seconds This news release is available in German. Research teams at the Helmholtz-Zentrum Berlin and at the University of Limerick, ...

Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults

2014-01-22
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults A second systematic review of a diagnostic test for tuberculosis (TB) endorsed by the World Health Organisation (WHO), has confirmed the accuracy of the test. The updated ...

Hearing loss linked to accelerated brain tissue loss

2014-01-22
Hearing loss linked to accelerated brain tissue loss Although the brain becomes smaller with age, the shrinkage seems to be fast-tracked in older adults with hearing loss, according to the results of a study by researchers from Johns Hopkins and the National ...

Lawrence Livermore 'space cops' to help control traffic in space

2014-01-22
Lawrence Livermore 'space cops' to help control traffic in space A team of Lawrence Livermore National Laboratory scientists are using mini-satellites that work as "space cops" to help control traffic in space. The scientists used a series of six ...

Putting 'Adam' in his rightful place in evolutionary history

2014-01-22
Putting 'Adam' in his rightful place in evolutionary history Our most common male ancestor walked the earth 209,000 years ago – earlier than scientists commonly thought - according to new research from the University of Sheffield. The pioneering study, ...

European epilepsy consortium identifies new gene for severe childhood epilepsy

2014-01-22
European epilepsy consortium identifies new gene for severe childhood epilepsy A novel combination of technologies made this possible A European consortium of epilepsy researchers has reported the discovery of a new gene involved in ...

LAST 30 PRESS RELEASES:

New study sheds light on Milky Way's mysterious chemical history

Could altering the daily timing of immunotherapy improve survival in people with cancer?

Weaving secondary battery electrodes with fibers and tying them like ropes for both durability and performance

Using social media may impair children’s attention

Science briefing: An update on GLP-1 drugs for obesity

Lower doses of immunotherapy for skin cancer give better results

Why didn’t the senior citizen cross the road? Slower crossings may help people with reduced mobility

ASH 2025: Study suggests that a virtual program focusing on diet and exercise can help reduce side effects of lymphoma treatment

A sound defense: Noisy pupae puff away potential predators

Azacitidine–venetoclax combination outperforms standard care in acute myeloid leukemia patients eligible for intensive chemotherapy

Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes

New findings support a chemo-free approach for treating Ph+ ALL

Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL

University of Cincinnati experts present research at annual hematology event

ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial

ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer

ASH 2025: New study shows that patients can safely receive stem cell transplants from mismatched, unrelated donors

Protective regimen allows successful stem cell transplant even without close genetic match between donor and recipient

Continuous and fixed-duration treatments result in similar outcomes for CLL

Measurable residual disease shows strong potential as an early indicator of survival in patients with acute myeloid leukemia

Chemotherapy and radiation are comparable as pre-transplant conditioning for patients with b-acute lymphoblastic leukemia who have no measurable residual disease

Roughly one-third of families with children being treated for leukemia struggle to pay living expenses

Quality improvement project results in increased screening and treatment for iron deficiency in pregnancy

IV iron improves survival, increases hemoglobin in hospitalized patients with iron-deficiency anemia and an acute infection

Black patients with acute myeloid leukemia are younger at diagnosis and experience poorer survival outcomes than White patients

Emergency departments fall short on delivering timely treatment for sickle cell pain

Study shows no clear evidence of harm from hydroxyurea use during pregnancy

Long-term outlook is positive for most after hematopoietic cell transplant for sickle cell disease

Study offers real-world data on commercial implementation of gene therapies for sickle cell disease and beta thalassemia

Early results suggest exa-cel gene therapy works well in children

[Press-News.org] UCLA researchers develop risk calculator to predict survival in heart failure patients